267 related articles for article (PubMed ID: 33989225)
1. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
John BV; Khakoo NS; Schwartz KB; Aitchenson G; Levy C; Dahman B; Deng Y; Goldberg DS; Martin P; Kaplan DE; Taddei TH
Am J Gastroenterol; 2021 Sep; 116(9):1913-1923. PubMed ID: 33989225
[TBL] [Abstract][Full Text] [Related]
2. Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis.
John BV; Aitcheson G; Schwartz KB; Khakoo NS; Dahman B; Deng Y; Goldberg D; Martin P; Taddei TH; Levy C; Kaplan DE
Hepatology; 2021 Aug; 74(2):879-891. PubMed ID: 33636012
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
4. Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis.
John BV; Dahman B; Deng Y; Khakoo NS; Taddei TH; Kaplan DE; Levy C
Liver Int; 2022 Feb; 42(2):384-393. PubMed ID: 34614294
[TBL] [Abstract][Full Text] [Related]
5. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
[TBL] [Abstract][Full Text] [Related]
6. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
[TBL] [Abstract][Full Text] [Related]
8. Decreased infiltration of CD4
Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
[TBL] [Abstract][Full Text] [Related]
9. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.
Kuiper EM; Hansen BE; Adang RP; van Nieuwkerk CM; Timmer R; Drenth JP; Spoelstra P; Brouwer HT; Kuyvenhoven JP; van Buuren HR;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1495-502. PubMed ID: 21389798
[TBL] [Abstract][Full Text] [Related]
10. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular Carcinoma in Primary Biliary Cholangitis.
Sy AM; Ferreira RD; John BV
Clin Liver Dis; 2022 Nov; 26(4):691-704. PubMed ID: 36270724
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis.
Shi TY; Zhang LN; Chen H; Wang L; Shen M; Zhang X; Zhang FC
World J Gastroenterol; 2013 Feb; 19(7):1111-8. PubMed ID: 23467321
[TBL] [Abstract][Full Text] [Related]
14. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
[TBL] [Abstract][Full Text] [Related]
15. Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis.
Umemura T; Sekiguchi T; Joshita S; Yamazaki T; Fujimori N; Shibata S; Ichikawa Y; Komatsu M; Matsumoto A; Shums Z; Norman GL; Tanaka E; Ota M
Liver Int; 2017 Jun; 37(6):897-905. PubMed ID: 27860118
[TBL] [Abstract][Full Text] [Related]
16. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
[No Abstract] [Full Text] [Related]
17. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis.
Hofer BS; Burghart L; Halilbasic E; Simbrunner B; Petrenko O; Mandorfer M; Stättermayer AF; Trauner M; Reiberger T
Aliment Pharmacol Ther; 2024 Apr; 59(8):962-972. PubMed ID: 38409879
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis.
Gordon SC; Wu KH; Lindor K; Bowlus CL; Rodriguez CV; Anderson H; Boscarino JA; Trudeau S; Rupp LB; Haller IV; Romanelli RJ; VanWormer JJ; Schmidt MA; Daida YG; Sahota A; Vincent J; Zhang T; Li J; Lu M;
Am J Gastroenterol; 2020 Feb; 115(2):262-270. PubMed ID: 31985529
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
[TBL] [Abstract][Full Text] [Related]
20. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
